Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
01 05 2022
Historique:
received: 13 10 2021
accepted: 04 02 2022
pubmed: 24 3 2022
medline: 18 5 2022
entrez: 23 3 2022
Statut: ppublish

Résumé

To assess the incidence of remission of type 2 diabetes in routine care settings. People with type 2 diabetes (HbA1c ≥48 mmol/mol [6.5%] or <48 mmol/mol [6.5%] with a prescription for glucose-lowering medications) alive on 1 April 2018 were identified from a national collation of health records in England and followed until 31 December 2019. Remission was defined as two HbA1c measurements of <48 mmol/mol (6.5%) at least 182 days apart, with no prescription for glucose-lowering medications 90 days before these measurements. In 2,297,700 people with type 2 diabetes, the overall incidence of remission per 1,000 person-years was 9.7 (95% CI 9.6-9.8) and 44.9 (95% CI 44.0-45.7) in 75,610 (3.3%) people who were diagnosed <1 year. In addition to shorter duration of diagnosis, baseline factors associated with higher odds of remission were no prescription for glucose-lowering medication, lower HbA1c and BMI, BMI reduction, White ethnicity, female sex, and lower socioeconomic deprivation. Among 8,940 (0.4%) with characteristics associated with remission (diagnosed <2 years, HbA1c <53 mmol/mol [7.0%], prescribed metformin alone or no glucose-lowering medications, BMI reduction of ≥10%), incidence of remission per 1,000 person-years was 83.2 (95% CI 78.7-87.9). Remission of type 2 diabetes was generally infrequent in routine care settings but may be a reasonable goal for a subset of people who lose a significant amount of weight shortly after diagnosis. Policies that encourage intentional remission of type 2 diabetes should seek to reduce the ethnic and socioeconomic inequalities identified.

Identifiants

pubmed: 35320360
pii: 144853
doi: 10.2337/dc21-2136
pmc: PMC9174970
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin A 0
Hypoglycemic Agents 0

Banques de données

figshare
['10.2337/figshare.19165148']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1151-1161

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom

Informations de copyright

© 2022 by the American Diabetes Association.

Références

JAMA. 2014 Jun 11;311(22):2297-304
pubmed: 24915261
Diabetes Care. 2016 Jun;39(6):924-33
pubmed: 27222550
Diabetologia. 2020 Aug;63(8):1542-1553
pubmed: 32435821
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
Diabet Med. 2021 Sep;38(9):e14616
pubmed: 34062007
Diabetes Care. 2014 Dec;37(12):3188-95
pubmed: 25231895
Diabetes Care. 2012 Aug;35(8):1746-8
pubmed: 22699291
Diabet Med. 2020 Apr;37(4):681-688
pubmed: 31479535
Diabetes Metab Res Rev. 2018 Sep;34(6):e3015
pubmed: 29663623
Diabetes Care. 2021 Aug 30;:
pubmed: 34462270
N Engl J Med. 2012 Apr 26;366(17):1577-85
pubmed: 22449317
JAMA. 2012 Dec 19;308(23):2489-96
pubmed: 23288372
Lancet Diabetes Endocrinol. 2019 May;7(5):344-355
pubmed: 30852132
Diabetologia. 2016 May;59(5):945-53
pubmed: 26983924
Diabet Med. 2012 Feb;29(2):181-9
pubmed: 21883428

Auteurs

Naomi Holman (N)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.

Sarah H Wild (SH)

Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, U.K.

Kamlesh Khunti (K)

Diabetes Research Centre, University of Leicester, Leicester, U.K.

Peter Knighton (P)

Analytical Services-Population Health, Clinical Audit and Specialist Care, NHS Digital, Leeds, U.K.

Jackie O'Keefe (J)

Analytical Services-Population Health, Clinical Audit and Specialist Care, NHS Digital, Leeds, U.K.

Chirag Bakhai (C)

NHS England and NHS Improvement, London, U.K.

Bob Young (B)

Diabetes UK, London, U.K.

Naveed Sattar (N)

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, U.K.

Jonathan Valabhji (J)

NHS England and NHS Improvement, London, U.K.
Department of Diabetes and Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, U.K.
Division of Metabolism, Digestion and Reproduction, Imperial College London, London, U.K.

Edward W Gregg (EW)

School of Public Health, Imperial College London, London, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH